Evidence map›Paper›PMID 22819579›Full record

ReviewMagnetic resonance imaging2012

Quantitative assessment of dynamic PET imaging data in cancer imaging.

Mark Muzi, Finbarr O'Sullivan, David A Mankoff, Robert K Doot, Larry A Pierce, Brenda F Kurland, Hannah M Linden, Paul E Kinahan

Abstract readReview
In one paragraph

Review in Magnetic resonance imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Validation of Lung [Molecular imaging and biology · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Combined whole-body dynamic and static PET/CT with low-dose [European journal of nuclear medicine and molecular imaging · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Quantitation of dynamic total-body PET imaging: recent developments and future perspectives.European journal of nuclear medicine and molecular imaging · 2023
    Review
  20. Diagnostic Value of DynamicDiagnostics (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mark MuziDepartment of Radiology, University of Washington, Seattle, WA 98195-6004, USA. muzi@u.washington.edu
Finbarr O'Sullivan
David A Mankoff
Robert K Doot
Larry A Pierce
Brenda F Kurland
Hannah M Linden
Paul E Kinahan

Funding

RadiochemistryP01CA042045 · NCI · UNIVERSITY OF WASHINGTON · PI SPENCE, ALEXANDER M · 1986 to 2015
$23.2M
The Physi(ologi)cal Microenvironment and its Role in Tumor Invasion and MetastaseU54CA143970 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GATENBY, ROBERT A · 2009 to 2014
$9.3M
Advanced PET/CT Imaging for Improving Clinical TrialsU01CA148131 · NCI · UNIVERSITY OF WASHINGTON · PI KINAHAN, PAUL E., LINDEN, HANNAH M · 2010 to 2019
$6.0M
Patient-specific predictive modeling that integrates advanced cancer imagingR01CA164371 · NCI · UNIVERSITY OF WASHINGTON · PI KINAHAN, PAUL E., SWANSON, KRISTIN R · 2011 to 2015
$4.5M
NCI NIH HHS P01 CA042045NCI NIH HHS P01-CA042045NCI NIH HHS R01 CA164371NCI NIH HHS R01-CA164371NCI NIH HHS U01 CA148131NCI NIH HHS U01-CA148131NCI NIH HHS U54 CA143970
6 · The paper itself

Abstract

Clinical imaging in positron emission tomography (PET) is often performed using single-time-point estimates of tracer uptake or static imaging that provides a spatial map of regional tracer concentration. However, dynamic tracer imaging can provide considerably more information about in vivo biology by delineating both the temporal and spatial pattern of tracer uptake. In addition, several potential sources of error that occur in static imaging can be mitigated. This review focuses on the application of dynamic PET imaging to measuring regional cancer biologic features and especially in using dynamic PET imaging for quantitative therapeutic response monitoring for cancer clinical trials. Dynamic PET imaging output parameters, particularly transport (flow) and overall metabolic rate, have provided imaging end points for clinical trials at single-center institutions for years. However, dynamic imaging poses many challenges for multicenter clinical trial implementations from cross-center calibration to the inadequacy of a common informatics infrastructure. Underlying principles and methodology of PET dynamic imaging are first reviewed, followed by an examination of current approaches to dynamic PET image analysis with a specific case example of dynamic fluorothymidine imaging to illustrate the approach.

Indexed as

CalibrationClinical Trials as TopicFluorodeoxyglucose F18HumansImage Processing, Computer-AssistedMedical OncologyMulticenter Studies as TopicNeoplasmsPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsTomography, X-Ray ComputedFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID22819579
PMCPMC3466344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.